NCT00410605 · OUTCOME

Effect of Bev/Rev on Markers of Myeloma Activity in Myeloma Cells and Stromal Cells at 3 Months Post-baseline

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma · Source last updated 2017-09-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: mg per liter
Interval / dispersion: Standard Deviation
Time frame: Up to Course 4 Day 1 (3 Months Post-baseline)

What was measured

A Wilconxon signed-rank test conducted to determine if biomarker levels differed between baseline levels and those after three full cycles of treatment for all patients.

Groups in this outcome

Bevacizumab, Dexamethasone, and Lenalidomide

Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. bevacizumab: Given IV lenalidomide: Given orally dexamethasone: Given orally

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Bevacizumab, Dexamethasone, and Lenalidomide	34

Reported measurements

IL-6 level range

Values in mg per liter · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Bevacizumab, Dexamethasone, and Lenalidomide	5.5	3.4	Not reported	Not reported	Not reported

MIP-1 level range

Values in mg per liter · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Bevacizumab, Dexamethasone, and Lenalidomide	0.047	0.044	Not reported	Not reported	Not reported

VEGF level range

Values in mg per liter · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Bevacizumab, Dexamethasone, and Lenalidomide	0.054	0.042	Not reported	Not reported	Not reported

VEGFR1 level range

Values in mg per liter · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Bevacizumab, Dexamethasone, and Lenalidomide	0.12	0.088	Not reported	Not reported	Not reported

VEGFR2 level range

Values in mg per liter · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Bevacizumab, Dexamethasone, and Lenalidomide	8.17	2.29	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
3.4
value
5.5
title
IL-6 level range
categories
measurements
group Id
OG000
spread
0.044
value
0.047
title
MIP-1 level range
categories
measurements
group Id
OG000
spread
0.042
value
0.054
title
VEGF level range
categories
measurements
group Id
OG000
spread
0.088
value
0.12
title
VEGFR1 level range
categories
measurements
group Id
OG000
spread
2.29
value
8.17
title
VEGFR2 level range

denoms

counts
group Id
OG000
value
34
units
Participants

description

A Wilconxon signed-rank test conducted to determine if biomarker levels differed between baseline levels and those after three full cycles of treatment for all patients.

dispersion Type

Standard Deviation

groups

description
Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. bevacizumab: Given IV lenalidomide: Given orally dexamethasone: Given orally
id
OG000
title
Bevacizumab, Dexamethasone, and Lenalidomide

param Type

MEAN

reporting Status

POSTED

time Frame

Up to Course 4 Day 1 (3 Months Post-baseline)

title

Effect of Bev/Rev on Markers of Myeloma Activity in Myeloma Cells and Stromal Cells at 3 Months Post-baseline

type

SECONDARY

unit Of Measure

mg per liter

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice